ASCLETIS-B (01672) surged over 4% in afternoon trading. As of press time, the stock was up 4.4% to HK$11.63 with a turnover of HK$37.01 million.

On the news front, on September 9, Ascletis announced that its small molecule GLP-1R agonist ASC30 subcutaneous depot formulation for weight maintenance demonstrated an apparent half-life of 75 days in obese subjects. This indicates that ASC30 has the potential to develop a long-term weight management maintenance regimen with quarterly dosing intervals in the future.

The ASC30 weight maintenance formulation was developed using Ascletis' Ultra-Long Acting Platform (ULAP). Notably, the company's controlling shareholders recently made a voluntary lock-up commitment, pledging not to sell any shares of the company until the following three clinical data readouts: topline data from the U.S. Phase I clinical study of ASC47 in combination with semaglutide in obese subjects, expected by the end of September 2025; topline data from the U.S. 13-week Phase IIa clinical study of ASC30 oral tablets in obese or overweight subjects, expected in December 2025; and topline data from the U.S. Phase I single ascending dose study of ASC50 in healthy subjects, also expected in December 2025.